MSFT 430.59 0.8407% AAPL 222.5 -0.1212% NVDA 119.1 -0.0336% GOOGL 157.46 1.7907% GOOG 158.37 1.8195% AMZN 186.49 -0.2727% META 524.62 -0.1865% AVGO 167.69 1.902% TSLA 230.29 0.2089% TSM 172.5 0.6242% LLY 923.71 -1.2096% V 287.35 0.6938% JPM 204.32 -1.1036% UNH 594.32 1.0027% NVO 137.0 0.2488% WMT 80.6 1.18% LVMUY 134.665 -0.226% XOM 111.15 -0.0719% LVMHF 675.14 0.1691% MA 493.36 0.254%
Last update at 2024-09-13T20:00:00Z
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Fri 10 Mar 23, 01:35 PMLife Sciences Virtual Investor Forum Agenda Announced for March 9th
Tue 07 Mar 23, 01:35 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Minority interest | - | - | - | - | - |
| Net income | -64.87500M | -58.11800M | -56.53700M | -48.67100M | -48.43500M |
| Selling general administrative | 16.55M | 15.39M | 13.54M | 14.73M | 15.72M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.18M | 1.75M | 0.55M | 2.22M | 2.52M |
| Reconciled depreciation | 2.52M | 2.44M | 2.64M | 2.70M | 2.42M |
| Ebit | -67.41900M | -63.20800M | -63.10200M | -57.11100M | -53.65100M |
| Ebitda | -63.62500M | -60.76500M | -60.46600M | -54.40900M | -51.23000M |
| Depreciation and amortization | 3.79M | 2.44M | 2.64M | 2.70M | 2.42M |
| Non operating income net other | - | 0.21M | 1.30M | 3.06M | 2.84M |
| Operating income | -67.41900M | -60.76500M | -60.46600M | -54.40900M | -51.23000M |
| Other operating expenses | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M |
| Interest expense | 0.00200M | 0.00200M | 0.00600M | 0.02M | 0.04M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.27M | 0.21M | 1.30M | 3.06M | 2.84M |
| Net interest income | 1.26M | 0.21M | 1.30M | 3.04M | 2.80M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.27200M | -2.44300M | -2.63600M | -2.70200M | 2.84M |
| Total revenue | 1.18M | 1.75M | 0.55M | 2.22M | 2.52M |
| Total operating expenses | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M |
| Cost of revenue | - | - | - | - | 0.00000M |
| Total other income expense net | 1.27M | 0.20M | 1.29M | 3.04M | 2.79M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Net income applicable to common shares | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 75.55M | 110.86M | 174.74M | 143.84M | 188.57M |
| Intangible assets | - | - | - | 9.59M | 16.38M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.15M | 0.17M | 0.31M | 0.25M | 0.65M |
| Total liab | 32.90M | 28.25M | 27.47M | 28.70M | 31.67M |
| Total stockholder equity | 42.66M | 82.61M | 147.27M | 115.14M | 156.91M |
| Deferred long term liab | - | - | 9.31M | 9.59M | 16.38M |
| Other current liab | 11.16M | 5.29M | 4.40M | 3.77M | 3.95M |
| Common stock | 0.01000M | 0.07M | 0.07M | 0.04M | 0.03M |
| Capital stock | 0.01000M | 0.07M | 0.07M | 0.04M | 0.03M |
| Retained earnings | -414.30100M | -357.01900M | -290.87200M | -230.31100M | -171.13800M |
| Other liab | - | - | - | 0.13M | - |
| Good will | - | - | - | - | - |
| Other assets | - | 9.40M | 10.41M | 10.69M | 17.54M |
| Cash | 23.96M | 15.86M | 16.44M | 32.51M | 26.18M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 20.40M | 12.12M | 10.08M | 8.30M | 8.86M |
| Current deferred revenue | 3.00M | 0.88M | 0.53M | - | 0.54M |
| Net debt | -6.68500M | 4.44M | 4.16M | -9.70100M | -1.17000M |
| Short term debt | 4.78M | 4.17M | 3.20M | 2.53M | 2.21M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 17.27M | 20.30M | 20.59M | 22.81M | 25.01M |
| Other stockholder equity | 456.94M | 439.72M | 438.11M | 345.39M | 327.90M |
| Property plant equipment | - | 21.68M | 9.09M | 26.30M | 30.28M |
| Total current assets | 49.91M | 79.78M | 136.63M | 100.44M | 127.07M |
| Long term investments | - | 0.00000M | 8.04M | 0.00000M | 7.50M |
| Net tangible assets | - | 82.61M | 147.27M | 115.14M | 156.91M |
| Short term investments | 23.79M | 61.77M | 112.15M | 67.94M | 93.39M |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 1.46M | 1.78M | 1.94M | 2.00M | 2.17M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00600M | -0.16100M | -0.04500M | 0.01M | 0.11M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.07M | 0.04M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -290.87200M | -230.31100M | -171.13800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 6.84M | 9.40M | 20.98M | 23.03M | 48.48M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 25.64M | 31.08M | 38.11M | 43.40M | 61.50M |
| Capital lease obligations | 17.27M | 20.30M | 20.59M | 22.81M | 25.01M |
| Long term debt total | - | - | - | - | 0.00200M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 58.35M | -52.57400M | 32.48M | 12.05M | -81.54700M |
| Change to liabilities | 0.70M | 0.41M | -0.89300M | -0.93500M | -0.25700M |
| Total cashflows from investing activities | 58.35M | -53.25300M | 32.48M | 10.80M | -87.20100M |
| Net borrowings | -0.01300M | 0.04M | -0.20800M | -0.26600M | -0.42700M |
| Total cash from financing activities | -2.04000M | 89.38M | 13.39M | 79.60M | 82.48M |
| Change to operating activities | -0.32500M | -0.86900M | 12.26M | -30.36000M | 1.40M |
| Net income | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Change in cash | -0.57700M | -16.06900M | 6.32M | 14.93M | -47.18800M |
| Begin period cash flow | 17.54M | 33.60M | 27.28M | 12.35M | 59.54M |
| End period cash flow | 16.96M | 17.54M | 33.60M | 27.28M | 12.35M |
| Total cash from operating activities | -56.88800M | -52.19800M | -39.55300M | -75.46800M | -42.47000M |
| Issuance of capital stock | 0.29M | 89.09M | 13.54M | 57.00M | 82.67M |
| Depreciation | 2.52M | 2.44M | 2.64M | 2.70M | 2.42M |
| Other cashflows from investing activities | - | - | - | 12.05M | -81.54700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | -2.51800M | 81.04M | 13.54M | 79.87M | 82.91M |
| Other cashflows from financing activities | 0.20M | 0.30M | 0.06M | 22.87M | 0.24M |
| Change to netincome | - | 3.36M | 5.62M | 4.13M | 4.33M |
| Capital expenditures | 0.73M | 0.68M | 0.40M | 1.25M | 5.65M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | 1.89M | 13.32M | -28.71400M | 0.88M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -16.06900M | 6.32M | 14.93M | -47.18800M |
| Change in working capital | 0.72M | 0.20M | 11.36M | -31.01900M | 0.62M |
| Stock based compensation | 3.64M | 3.36M | 3.91M | 4.13M | 4.32M |
| Other non cash items | 2.38M | 2.10M | 1.74M | 1.37M | -1.39300M |
| Free cash flow | -57.61600M | -52.87700M | -39.94800M | -76.71900M | -48.12400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SYBX Synlogic Inc |
-0.0401 2.78% | 1.40 | - | - | 5.92 | 1.41 | 0.28 | 0.18 |
| NVO Novo Nordisk A/S |
0.34 0.25% | 137.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.25 0.90% | 137.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
6.72 1.40% | 485.37 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-11.11 0.95% | 1153.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
301 Binney Street, Cambridge, MA, United States, 02142
| Name | Title | Year Born |
|---|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Pres, CEO & Director | 1976 |
| Mr. Antoine Awad | Chief Operating Officer | 1980 |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1981 |
| Dr. James J. Collins Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1966 |
| Mr. Michael Jensen | Chief Financial Officer | NA |
| Dr. David L. Hava Ph.D. | Chief Scientific Officer | 1975 |
| Dr. Elizabeth Wolffe | Head of Investor Relations & Corp. Communications | NA |
| Mr. Brendan St. Amant | Gen. Counsel & Corp. Sec. | NA |
| Mr. Ajay Munshi | VP of Corp. Devel. | NA |
| Mr. Adam Thomas | Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...